FDA turns thumbs down on Allergan's optimistic case for uterine fibroid drug as liver damage threat torpedoes application
One of Allergan’s $AGN top late-stage drugs just ran into a brick wall at the FDA.
The company noted Tuesday evening that the agency turned …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
